Table 1 Characteristics of ulcerative colitis (UC) and Crohn’s disease (CD) patients with non-response to biological treatment, severe outcome, remission and normal controls. Values are in actual number or mean (range). For further details, see text. * The Montreal classification for IBD. # Mucosal TNF expression below 7500 copies/μg total RNA was a selection criterium for these groups

Number

n = 21

n = 12

n = 13

n = 10

n = 13

n = 15

n = 16

Age

40.3 (18–71)

43.1 (27–56

34.4 (22–67)

37.2 (22–58)

48.4 (20–76)

36.7 (20–54)

52.8 (19–83)

Sex (female/male)

7/14

4/8

7/6

5/5

4/9

8/7

7/9

Smoking current/earlier/never

2/5/7

2/7/1

0/5/6

2/2/4

1/6/3

1/1/5

3/7/4

Area involved (UC) E1/E2/E3*

1/9/11

2/6/5

0/7/6

Area involved (CD) L1/L2/L3/L4*

1/4/7/0

2/3/4/1

4/5/6/0

Duration of disease (years)

8.7 (1–35)

11.5 (3–40)

8.8 (2–28)

7.9 (2–24)

Treatment duration (weeks)

91.4 (17–270)

154.3 (21–634)

149 (47–432)

133 (50–321)

Anti-TNF/VDZ/UST

21/0/0

10/2/0

13/0/0

13/1/1

Primary/secondary non-response

12/9

10/2

Mucosal TNF gene transcription

17,923 (1700–61,100)

21,692 (7600–46,400)

19,100 (12600–30,700)

27,970 (4000–63,400)

#4088 (350–7000)

#3607 (200–6100)

4869 (300–11,400)

UCDAI/CDAI score

9.4 (3–12, n = 19)

279 (180–483, n = 10)

9.8 (6–12)

239 (176–295, n = 4)

0,3 (0–1, n = 11)

37 (0–114, n = 8)

MAYO/SES score

2.7 (2–3)

10.9 (3–22)

2.5 (2–3, n = 11)

10 (9–11, n = 2)

0,3 (0–1, n = 11)

0 (0)

Calprotectin mg/kg

1030 (50–3000)

821 (60–3000)

1366 (240–3000)

648 (25–1585)

46 (25–150, n = 11)

48 (20–185, n = 13)

25 (< 25–25, n = 3))

Fecal bacterial culture performed (yes/no)

11/10

4/8

Concentration of biologic agent measured (yes/no)

19/2

10/2